Summary
Updated Aug 30, 2026
Gerd Auffarth is Director of Outlook Therapeutics, Inc. (OTLK). 2 SEC Form 4 filings on record going back to 2024, most recently on 1 October 2025.
Trading Pattern
InsiderAlpha's records for Gerd Auffarth go back to 2024: 2 primary Form 4 filings, an average of 0.7 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Gerd Auffarth files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ghiath M. Sukhtian - $7.50M of OTLK open-market activity in the last 12 months
- Kurt J. Hilzinger - $177K of OTLK open-market activity in the last 12 months
- Faisal Ghiath Sukhtian - $150K of OTLK open-market activity in the last 12 months
- Yezan Munther Haddadin - $39K of OTLK open-market activity in the last 12 months
- Randy H. Thurman - $2K of OTLK open-market activity in the last 12 months
- Robert Charles Jahr - of OTLK open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Gerd Auffarth?
Gerd Auffarth is a corporate insider, tracked as Director of Outlook Therapeutics, Inc. (OTLK). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Gerd Auffarth last file a Form 4?
The most recent primary Form 4 on record is dated 1 October 2025, one of 2 filings going back to 2024.
Where can I see all of Gerd Auffarth's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Gerd Auffarth and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial